Ninepoint Partners LP Invests $502,000 in Eli Lilly and Company $LLY

Ninepoint Partners LP bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 658 shares of the company’s stock, valued at approximately $502,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Caitlin John LLC bought a new stake in shares of Eli Lilly and Company in the third quarter valued at about $91,000. Creative Financial Designs Inc. ADV increased its stake in Eli Lilly and Company by 0.4% during the third quarter. Creative Financial Designs Inc. ADV now owns 27,175 shares of the company’s stock valued at $20,735,000 after acquiring an additional 99 shares during the period. Power Wealth Management LLC raised its holdings in Eli Lilly and Company by 185.8% in the 3rd quarter. Power Wealth Management LLC now owns 1,706 shares of the company’s stock valued at $1,302,000 after acquiring an additional 1,109 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in Eli Lilly and Company by 12.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 852,509 shares of the company’s stock valued at $650,464,000 after acquiring an additional 92,689 shares in the last quarter. Finally, Generali Investments Management Co LLC lifted its position in shares of Eli Lilly and Company by 35.3% in the 3rd quarter. Generali Investments Management Co LLC now owns 12,567 shares of the company’s stock worth $9,589,000 after acquiring an additional 3,281 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 2.8%

NYSE:LLY opened at $1,050.39 on Friday. The company has a market cap of $990.90 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 1.19 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock’s fifty day moving average price is $1,053.15 and its two-hundred day moving average price is $928.02. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the previous year, the company posted $5.32 earnings per share. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 30.15%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Daiwa Securities Group boosted their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a research note on Thursday. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Finally, TD Cowen increased their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,229.59.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Topline ACHIEVE‑3 results for type 2 diabetes showed meaningful A1C and weight benefits for Lilly’s oral GLP‑1 in a head‑to‑head setting, reinforcing the drug’s commercial and regulatory potential. Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
• Positive Sentiment: Detailed Phase 3/Lancet results show orforglipron outperformed oral semaglutide on A1C and weight in ACHIEVE‑3, strengthening Lilly’s case for market share and supporting upcoming regulatory timelines (U.S. obesity decision possible in Q2). Orforglipron Lancet results PR Newswire
• Positive Sentiment: CHMP issued a positive opinion for expanded EU use of Olumiant (baricitinib) in adolescents with severe alopecia areata — a near‑term regulatory win that expands labeled indications and revenue opportunities in Europe. Olumiant CHMP positive opinion PR Newswire
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $1,250 PT, signaling institutional confidence in Lilly’s obesity leadership; coupled with recent price‑target increases from other shops, this boosts investor conviction. RBC Capital initiates Eli Lilly
• Positive Sentiment: High‑profile media/TV endorsements (e.g., Jim Cramer recommending Lilly over Novo Nordisk) are supportive for retail flows and sentiment toward LLY. Jim Cramer Recommends Eli Lilly
• Neutral Sentiment: Reuters published additional trial safety data giving a more detailed picture of side effects — useful context for regulators and investors but not a clear negative or positive on balance. Reuters: additional data on weight-loss pill
• Neutral Sentiment: Health‑care stocks broadly moved higher today, which can amplify sector leaders’ moves but may reflect macro/flow dynamics rather than company‑specific fundamentals. Sector Update: Health Care Stocks Higher
• Negative Sentiment: Smaller rivals (e.g., Viking Therapeutics) and other entrants remain active in the obesity space — a potential long‑term competitive risk that could pressure pricing and market share over time. Viking Therapeutics profile

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.